Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment, Organ Transplantation Techniques and Outcomes, and Hepatitis C virus research.
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis
Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort
Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis
Prognosis of hospitalized patients with cirrhosis and acute kidney disease
Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis
Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis
Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID‐19: Systematic Review and Meta‐analysis
Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis
Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax
Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites
Impact of Chronic Kidney Disease on Outcomes in Cirrhosis
Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis
Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience
Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox
Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis
NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis
Liver transplantation in patients with multiple organ failures: Feasibility and outcomes
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis
Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort
Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes
Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures
A Karnofsky performance status–based score predicts death after hospital discharge in patients with cirrhosis
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection